Press Release Details
Magenta Therapeutics Announced It Will Present Clinical and Pre-Clinical Data from Across Immune and Blood System Reset Portfolio at European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting
– Magenta to present five abstracts showcasing data across clinical and pre-clinical pipeline, including mobilization and conditioning programs –
– Phase I clinical trial results confirm that MGTA-145 demonstrates same-day mobilization and collection of highly functional hematopoietic stem cells (HSCs) for transplant –
– Preclinical data from studies of Magenta’s CD45-ADC conditioning agent demonstrate successful immune reset to halt disease progression in multiple models of sclerosis, systemic sclerosis and inflammatory arthritis; as well as the ability to achieve complete chimerism in allogeneic hematopoietic stem cell transplant (HSCT) –
“Our presentations at EBMT showcase Magenta’s integrated approach towards bringing the curative power of blood and immune system reset through stem cell transplant to more patients and across more therapeutic areas,” said
All posters will be available to view on the EBMT website beginning
Clinical Data from MGTA-145 First-Line Stem Cell Mobilization Program:
Magenta is developing MGTA-145 as the new first-line standard of care for stem cell mobilization in a broad range of diseases, including autoimmune diseases, blood cancers and genetic diseases, such as sickle cell disease. MGTA-145, a CXCR2 agonist, works in combination with plerixafor, a CXCR4 antagonist, harnessing the physiological mechanism of stem cell mobilization to rapidly and robustly mobilize stem cells for collection and transplant.
Title: Phase 1 Clinical Study of MGTA-145 In Combination with Plerixafor Shows Rapid Single-Day Mobilization and Collection of CD34+ HSCs Without G-CSF (Abstract #B385)
These data provide further confirmation that MGTA-145, in combination with plerixafor, enables the same-day mobilization and collection of highly functional hematopoietic stem cells (HSCs) for transplant. Earlier this year, Magenta completed dosing in this Phase 1 trial, achieving all primary and secondary endpoints. In the second half of 2020, the Company plans to move the MGTA-145 program into multiple Phase 2 clinical trials to include both allogeneic and autologous transplant settings across multiple diseases. These trials will evaluate mobilization and collection of functional HSCs and engraftment of these cells after transplant.
Preclinical Data from Magenta’s Antibody-Drug Conjugate Conditioning Programs
Targeted, disease-modifying antibody-drug conjugates (ADCs) are designed to selectively and rapidly remove disease-causing cells in the body and enable immune and blood system reset and long-term engraftment, without the need for aggressive chemotherapy or radiation.
MGTA-117, the clinical candidate for ADC-based conditioning for stem cell transplant and gene therapy and Magenta’s most advanced conditioning program, is on track with IND-enabling toxicology studies ongoing and progress in GMP manufacturing. Magenta expects to generate initial clinical data in 2021.
Title: A Single Dose of
This collaborative study with the
Title: A Novel Targeted Approach to Achieve Immune System Reset: CD45-Targeted Antibody-Drug Conjugates Ameliorate Disease in Preclinical Autoimmune Disease Models and Enable Auto HSCT (Abstract #O030)
Magenta’s CD45-ADC program targets CD45, a protein expressed on immune cells and blood stem cells, and is designed to remove the cells that cause autoimmune diseases to enable curative immune reset. Magenta has identified a lead antibody for this program and IND-enabling work on CD45-ADC is progressing in 2020.
Preclinical data in this abstract show that a single dose of CD45-ADC removed disease-causing T-cells, enabling successful immune reset to halt disease progression and was well tolerated in three models of autoimmune disease: multiple sclerosis, systemic sclerosis and inflammatory arthritis.
Title: A CD45-Targeted Antibody Drug Conjugate Enables Allogeneic Hematopoietic Stem Cell Transplantation as a Single Agent in Mice (Abstract #A174)
Preclinical data in this abstract demonstrate that a single dose of CD45-ADC is fully myeloablative and enables complete chimerism in a full mismatch allogeneic hematopoietic stem cell transplant (HSCT), representing a substantial advance in establishing the potential of this targeted approach to conditioning to potently and safely enable immune reset in the allogeneic setting.
Title: High Dose Stem Cell Therapies, like MGTA-456, Enable Complete Neural and Peripheral Disease Cross-Correction Through Rapid and Robust Hematopoietic Engraftment (Abstract #A325)
Preclinical data in this abstract demonstrate rapid and durable peripheral, central nervous system (CNS) and skeletal disease cross-correction after transplantation of a high HSC dose. Mechanistic studies demonstrated that CNS disease cross-correction was due to robust microglial engraftment in the brain. MGTA-456 led to more robust microglial engraftment in NSG mice, suggesting that MGTA-456 may lead to rapid and durable disease resolution in the central nervous system.
Magenta is based in
Follow Magenta on Twitter: @magentatx.
This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “will,” “could”, “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “endeavor,” “potential,” “continue” or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks set forth under the caption “Risk Factors” in Magenta’s Annual Report on Form 10-K filed on